VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Elotuzumab & the role of monoclonal antibodies in the treatment of smoldering myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the efficacy and tolerability of monoclonal antibodies in the treatment of smoldering myeloma. Dr Cerchione namely mentions elotuzumab, which has shown impressive results in combination with lenalidomide, and emphasizes the importance of introducing novel treatment options in clinical practice in order to initiate treatment early and prevent progression of the disease. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter